BPG is committed to discovery and dissemination of knowledge
Featured Articles
7/16/2020 1:55:21 AM | Browse: 475 | Download: 1539
 |
Received |
|
2020-01-19 11:09 |
|
Peer-Review Started |
|
2020-01-19 11:10 |
|
First Decision by Editorial Office Director |
|
2020-05-01 03:24 |
|
Return for Revision |
|
2020-05-01 03:24 |
|
Revised |
|
2020-06-02 12:39 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-06-19 10:27 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-06-19 19:11 |
|
Articles in Press |
|
2020-06-19 19:11 |
|
Edit the Manuscript by Language Editor |
|
2020-06-26 13:28 |
|
Typeset the Manuscript |
|
2020-07-14 01:24 |
|
Publish the Manuscript Online |
|
2020-07-14 15:42 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Nan-Nan Zheng, Min Zhou, Fang Sun, Man-Xiu Huai, Yi Zhang, Chun-Ying Qu, Feng Shen and Lei-Ming Xu |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81472844 |
|
| Corresponding Author |
Lei-Ming Xu, MD, PhD, Chief Doctor, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Yangpu District, Shanghai 200092, China. xuleiming@xinhuamed.com.cn |
| Key Words |
Protein arginine methyltransferase; Programmed death-ligand-1 blockade; Pancreatic cancer; Combination therapy; Tumor microenvironment; Pancreatic ductal adenocarcinoma |
| Core Tip |
Pancreatic ductal adenocarcinoma exhibits marginal responses to immune checkpoint inhibitors targeting programmed death-ligand-1 (PD-L1), and the underlying mechanism remains poorly understood. PT1001B, an inhibitor of type I protein arginine methyltransferases (PRMTs), significantly enhanced the therapeutic efficacy of anti-PD-L1 mAb. PT1001B improved antitumor immunity by inhibiting PD-L1 expression on tumor cells, upregulating tumor infiltrating CD8+ T lymphocytes and decreasing PD-1+ leukocytes. In addition, PT1001B amplified the inhibitory effect of anti-PD-L1 on tumor cell proliferation and enhanced the induction of tumor cell apoptosis. PRMT1 downregulation was correlated with PD-L1 downregulation, thus PRMT1 is a potential therapeutic target. |
| Publish Date |
2020-07-14 15:42 |
| Citation |
Zheng NN, Zhou M, Sun F, Huai MX, Zheng Y, Qu CY, Shen F, Xu LM. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. World J Gastroenterol 2020; 26(26): 3737-3749 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i26/3737.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i26.3737 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
